The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Open accessAbstract
BACKGROUND: X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteomalacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that targets FGF-23, in patients with X-linked hypophosphatemia. METHODS: In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypophosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end of the normal range. The primary end point was the change from baseline to weeks 40 and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores indicating greater disease severity). In addition, the Radiographic Global Impression of Change was used to evaluate rachitic changes from baseline to week 40 and to week 64. Additional end points were changes in pharmacodynamic markers, linear growth, physical ability, and patient-reported outcomes and the incidence of adverse events. RESULTS: The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The mean serum phosphorus level increased after the first dose in both groups, and more than half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were maintained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption increased from baseline in both groups, with an overall mean increase of 0.98 mg per deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every-4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height z score increased in both groups, with greater improvement seen at all time points with every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain decreased. Nearly all the adverse events were mild or moderate in severity. CONCLUSIONS: In children with X-linked hypophosphatemia, treatment with burosumab improved renal tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical function and reduced pain and the severity of rickets. (Funded by Ultragenyx Pharmaceutical and Kyowa Hakko Kirin; ClinicalTrials.gov number, NCT02163577 ; EudraCT number, 2014-000406-35 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic management of hypophosphatemic rickets from infancy to adulthood
Linglart, A., Biosse-Duplan, M., Briot, K., Chaussain, C., Esterle, L., Guillaume-Czitrom, S., Kamenicky, P., Nevoux, J., Prié, D., Rothenbuhler, A., et al. (2014) · Endocrine Connections · doi:10.1530/ec-13-0103 · Cited by 331
Self-citation
Cited by
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Haffner, D., Emma, F., Eastwood, D. M., Biosse Duplan, M., Bacchetta, J., Schnabel, D., Wicart, P., Bockenhauer, D., Santos, F., Levtchenko, E., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0152-5 · Cited by 521
Self-citationImel, E. A., Glorieux, F. H., Whyte, M. P., Munns, C. F., Ward, L. M., Nilsson, O., Simmons, J. H., Padidela, R., Namba, N., Cheong, H. I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30654-3 · Cited by 379
Self-citationA Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Lee, K. S., & Lee, B. L. (2019) · Child's Nervous System · doi:10.1007/s00381-018-04042-7 · Cited by 8
Metadata
- Authors
- Carpenter, T. O., Whyte, M. P., Imel, E. A., Boot, A. M., Högler, W., Linglart, A., Padidela, R., van’t Hoff, W., Mao, M., Chen, C.-Y., Skrinar, A., Kakkis, E., San Martin, J., & Portale, A. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1987-1998
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2803769911
- Cited by
- 479
- References
- 1
- FWCI
- 38.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Burosumab Therapy in Children with X-Linked Hypophosphatemia. https://app.cochat.ai/papers/10.1056/nejmoa1714641
- The paper
- Carpenter, T. O., Whyte, M. P., Imel, E. A., Boot, A. M., Högler, W., Linglart, A., Padidela, R., van’t Hoff, W., Mao, M., Chen, C.-Y., Skrinar, A., Kakkis, E., San Martin, J., & Portale, A. A. (2018). Burosumab Therapy in Children with X-Linked Hypophosphatemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1714641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.